
|Videos|July 9, 2021
Implications of Phase 3 Trial Results Assessing Efficacy, Safety of Dapagliflozin in Patients With Type 2 Diabetes Hospitalized With COVID-19
Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed the implications of the DARE-19 trial results assessing dapagliflozin as a treatment for patients with type 2 diabetes hospitalized with COVID-19.
Advertisement
Pharmacy Times interviewed Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, on the results from the DARE-19 trial assessing the efficacy and safety of dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19.
During the discussion, Kosiborod explained the implications of the trial results on the treatment opportunities available for this patient population.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves XFG-Adapted COVID-19 Vaccine, mRNA for the 2026-2027 Season
2
Building the pharmacy of the future — trust, loyalty, and growth
3
Beyond the Transplant Center: IV Therapy in the Community
4
Incorporating Patient-Reported Symptoms into Treatment Plans
5


































































































